

Resource Summary Report

Generated by ASWG on Aug 10, 2026

Purified anti-human CD3

RRID:AB_571927

Type: Antibody

Proper Citation

BioLegend Cat# 317302, RRID:AB_571927

Antibody Information

URL: http://antibodyregistry.org/AB_571927

Proper Citation: BioLegend Cat# 317302, RRID:AB_571927

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, IHC-F

Antibody Name: Purified anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_571927

Vendor: BioLegend

Catalog Number: 317302

Alternative Catalog Numbers: 317301

Record Creation Time: 20250820T060023+0000

Record Last Update: 20250820T230311+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD3.

No alerts have been found for Purified anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Magno JC, et al. (2026) Engineering T Cells with a Tumor-Reactive Chimeric T-cell Receptor Reduces Exhaustion and Promotes Persistence to Elicit Enhanced Antitumor Responses. *Cancer research*, 86(11), 2688.

Wang J, et al. (2026) EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation. *Cell*.

Ward CJ, et al. (2026) Glucocorticoid receptor and RUNX transcription factors cooperatively drive CD8 T cell dysfunction in human cancer. *Cell reports*, 45(5), 117367.

Weber PAA, et al. (2026) Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control. *Cancer research communications*, 6(7), 1619.

Miller ML, et al. (2026) Fungal-derived cellobiose metabolic pathway fuels T cells to bypass intratumoral glucose competition. *Cell*, 189(6), 1717.

Podaza E, et al. (2026) Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. *Cell reports methods*, 6(6), 101339.

Kocher K, et al. (2026) Integrating complementary approaches reveals antigen-reactive CD4+ T cell states after SARS-CoV-2 vaccination. *iScience*, 29(6), 116175.

Sohal IS, et al. (2026) Exosome-like biogenesis from the Golgi releases extracellular vesicles lacking conventional tetraspanins that mediate immune evasion in cancer. *bioRxiv : the preprint server for biology*.

Codo AC, et al. (2026) Polystyrene microplastic-induced pathophysiology is driven by disruption of efferocytosis. *Immunity*, 59(3), 618.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy. *Cell reports. Medicine*, 6(9), 102324.

Wu Z, et al. (2025) Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy. *Cell*.

Schmidt KG, et al. (2025) Coronavirus replicase epitopes induce cross-reactive CD8 T cell responses in SARS-CoV-2-naive people with HIV-1. *iScience*, 28(3), 111949.

Sun MZ, et al. (2025) Immunotherapeutic targeting of NY-ESO-1 in malignant meningiomas with TCR-transduced T-cells. *Journal of neuro-oncology*.

Newsome RC, et al. (2025) Microbial-derived immunostimulatory small molecule augments anti-PD-1 therapy in lung cancer. *Cell reports. Medicine*, 102519.

Tu X, et al. (2024) S100A9+CD14+ monocytes contribute to anti-PD-1 immunotherapy resistance in advanced hepatocellular carcinoma by attenuating T cell-mediated antitumor function. *Journal of experimental & clinical cancer research : CR*, 43(1), 72.

Poch T, et al. (2024) Intergenic risk variant rs56258221 skews the fate of naive CD4+ T cells via miR4464-BACH2 interplay in primary sclerosing cholangitis. *Cell reports. Medicine*, 5(7), 101620.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. *Cancer cell*, 42(1), 35.

Vanhaver C, et al. (2024) Immunosuppressive low-density neutrophils in the blood of cancer patients display a mature phenotype. *Life science alliance*, 7(1).

Kögl T, et al. (2024) Patients and mice with deficiency in the SNARE protein SYNTAXIN-11 have a secondary B cell defect. *The Journal of experimental medicine*, 221(7).

Li X, et al. (2024) Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. *Immunity*, 57(7), 1603.